- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/735 - Récepteurs Fc
Détention brevets de la classe C07K 14/735
Brevets de cette classe: 667
Historique des publications depuis 10 ans
|
43
|
53
|
74
|
62
|
66
|
73
|
63
|
77
|
57
|
25
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immunitybio, Inc. | 507 |
49 |
| Regeneron Pharmaceuticals, Inc. | 4698 |
32 |
| FATE Therapeutics, Inc. | 235 |
24 |
| Cellectis | 415 |
17 |
| Tosoh Corporation | 1414 |
17 |
| The Trustees of the University of Pennsylvania | 4414 |
15 |
| NantKwest, Inc. | 48 |
13 |
| Xencor, Inc. | 412 |
11 |
| GI Innovation, Inc. | 59 |
11 |
| Novartis AG | 10263 |
10 |
| Autolus Limited | 266 |
10 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2999 |
10 |
| Zymeworks Inc. | 253 |
9 |
| Hoffmann-La Roche Inc. | 3783 |
8 |
| Chugai Seiyaku Kabushiki Kaisha | 1422 |
8 |
| Regents of the University of Minnesota | 2785 |
8 |
| SuppreMol GmbH | 25 |
7 |
| F. Hoffmann-La Roche AG | 7836 |
6 |
| 1Globe Biomedical Co., Ltd. | 31 |
6 |
| Ramot at Tel-Aviv University Ltd. | 1542 |
6 |
| Autres propriétaires | 390 |